Braun Stacey Associates Inc. Sells 16,367 Shares of Corcept Therapeutics Incorporated $CORT

Braun Stacey Associates Inc. cut its stake in Corcept Therapeutics Incorporated (NASDAQ:CORT) by 5.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 264,297 shares of the biotechnology company’s stock after selling 16,367 shares during the quarter. Braun Stacey Associates Inc. owned 0.25% of Corcept Therapeutics worth $9,198,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently modified their holdings of the company. Advisory Services Network LLC purchased a new stake in Corcept Therapeutics in the 3rd quarter valued at $25,000. Clearstead Advisors LLC grew its stake in shares of Corcept Therapeutics by 163.6% in the 3rd quarter. Clearstead Advisors LLC now owns 311 shares of the biotechnology company’s stock worth $26,000 after acquiring an additional 193 shares in the last quarter. Hantz Financial Services Inc. raised its holdings in shares of Corcept Therapeutics by 598.5% in the third quarter. Hantz Financial Services Inc. now owns 461 shares of the biotechnology company’s stock valued at $38,000 after purchasing an additional 395 shares during the last quarter. Larson Financial Group LLC raised its holdings in shares of Corcept Therapeutics by 2,326.3% in the third quarter. Larson Financial Group LLC now owns 461 shares of the biotechnology company’s stock valued at $38,000 after purchasing an additional 442 shares during the last quarter. Finally, Gould Capital LLC lifted its position in shares of Corcept Therapeutics by 50.0% during the third quarter. Gould Capital LLC now owns 600 shares of the biotechnology company’s stock valued at $50,000 after purchasing an additional 200 shares in the last quarter. Hedge funds and other institutional investors own 93.61% of the company’s stock.

Insider Transactions at Corcept Therapeutics

In related news, CEO Joseph K. Belanoff sold 26,198 shares of Corcept Therapeutics stock in a transaction dated Wednesday, March 25th. The stock was sold at an average price of $50.07, for a total value of $1,311,733.86. Following the completion of the sale, the chief executive officer owned 2,918,326 shares of the company’s stock, valued at approximately $146,120,582.82. This trade represents a 0.89% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director G Leonard Baker, Jr. acquired 100,000 shares of the company’s stock in a transaction on Tuesday, March 17th. The shares were acquired at an average cost of $33.14 per share, for a total transaction of $3,314,000.00. Following the completion of the acquisition, the director owned 1,146,631 shares of the company’s stock, valued at approximately $37,999,351.34. The trade was a 9.55% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last 90 days, insiders sold 86,198 shares of company stock worth $3,552,769. 20.80% of the stock is owned by company insiders.

Analysts Set New Price Targets

CORT has been the subject of a number of recent analyst reports. Wolfe Research raised shares of Corcept Therapeutics from an “underperform” rating to a “peer perform” rating in a research report on Thursday, March 26th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Corcept Therapeutics in a report on Monday, December 29th. UBS Group assumed coverage on Corcept Therapeutics in a report on Tuesday, December 16th. They set a “neutral” rating and a $95.00 price target on the stock. Canaccord Genuity Group boosted their price objective on Corcept Therapeutics from $100.00 to $110.00 and gave the stock a “buy” rating in a research report on Thursday, March 26th. Finally, HC Wainwright reduced their price objective on Corcept Therapeutics from $67.00 to $60.00 and set a “buy” rating for the company in a research note on Wednesday, March 25th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $77.67.

Corcept Therapeutics Stock Performance

Shares of CORT stock opened at $42.49 on Friday. The company has a quick ratio of 2.85, a current ratio of 2.92 and a debt-to-equity ratio of 0.01. The firm has a market cap of $4.52 billion, a P/E ratio of 51.82 and a beta of 0.25. The company has a 50 day moving average of $37.80 and a 200-day moving average of $59.61. Corcept Therapeutics Incorporated has a 12-month low of $28.66 and a 12-month high of $91.00.

Corcept Therapeutics (NASDAQ:CORT) last announced its quarterly earnings data on Tuesday, February 24th. The biotechnology company reported $0.20 earnings per share for the quarter, missing the consensus estimate of $0.33 by ($0.13). Corcept Therapeutics had a net margin of 12.96% and a return on equity of 15.19%. The firm had revenue of $202.13 million for the quarter, compared to the consensus estimate of $254.94 million. During the same period last year, the company posted $0.26 earnings per share. Corcept Therapeutics’s revenue for the quarter was up 11.1% on a year-over-year basis. Sell-side analysts anticipate that Corcept Therapeutics Incorporated will post 1.36 earnings per share for the current year.

Trending Headlines about Corcept Therapeutics

Here are the key news stories impacting Corcept Therapeutics this week:

• Neutral Sentiment: Several plaintiff firms and alert services (ClaimsFiler, Kaplan Fox, Bronstein Gewirtz, Schall, Glancy, Pomerantz, Rosen, etc.) remind investors of the April 21 lead‑plaintiff deadline and encourage affected shareholders to contact counsel; these notices increase publicity and bring more potential claimants into the case. ClaimsFiler Alert
• Neutral Sentiment: Multiple firms issued nearly identical deadline alerts over the last 48 hours (Kaplan Fox, Hagens Berman, Schall, Rosen, Glancy, Pomerantz), consolidating media attention around the litigation and the specified class period (Oct 31, 2024–Dec 30, 2025). Kaplan Fox / Globe & Mail
• Negative Sentiment: A plaintiff firm (Hagens Berman) highlights allegations the company made misstatements concerning FDA data — the complaint ties the suit to regulatory setbacks, which, if proven, could support larger investor claims and potential damages. This raises the prospect of material exposure beyond legal fees. Hagens Berman Alert
• Negative Sentiment: At least one alert frames the securities suit as following an FDA rejection and a recent federal court patent loss, signaling multiple catalysts behind investor claims (regulatory and IP setbacks increase downside risk to future revenues). Such combined regulatory/IP exposure typically amplifies potential settlement sizes and investor concern. GlobeNewswire / Hagens Berman
• Negative Sentiment: Coverage notes the original securities complaint was filed in February 2026; continued media and firm outreach suggests the litigation will remain an active headline risk through the April deadline and into any lead‑plaintiff selection, potentially affecting trading sentiment and valuation multiples. TipRanks summary

Corcept Therapeutics Company Profile

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.